

Texas Children's Cancer and Hematology Centers

# INTERNATIONAL NEUROBLASTOMA RESEARCH CONFERENCE

From Molecular Pathways to Novel Therapies

WEDNESDAY

May 3, 2017

2:00 pm - 6:00 pm

THURSDAY

May 4, 2017

7:15 am - 4:45 pm


Poster Session

4:45 pm - 6:00 pm

FRIDAY

May 5, 2017

7:15 am - 12:00 pm



**May 3, 2017 - May 5, 2017**

BioScience Research Collaborative  
Rice University  
6500 Main Street  
Houston, TX 77030

Baylor  
College of  
Medicine



Texas Children's  
Hospital

CANCER AND  
HEMATOLOGY CENTERS

## Wednesday, May 3

---

### ▲ SESSION I • 2:00 p.m. - 6:00 p.m.

**Session: Translational/Basic Science**

**Chairperson: Eveline Barbieri , Houston, TX**

- 2:00 p.m. – 2:30 p.m.**      **WELCOME**  
Jason Shoheit, MD, PhD  
Leonid S. Metelitsa, MD, PhD  
Jennifer Foster, MD, MPH  
*BCM, Pediatrics, Hematology/Oncology, Houston, TX*
- 2:30 p.m. – 2:55 p.m.**      **Jianhua Yang, MD, PhD**  
*BCM, Pediatrics, Hematology/Oncology, Houston, TX*  
FUNCTIONAL ANALYSIS OF CREB PATHWAY IN NEUROBLASTOMA.
- 2:55 p.m. – 3:20 p.m.**      **Giovanni Perini, PhD**  
*University of Bologna, Italy*  
ALTERING THE MYCN/MAX RATIO IN A FLY MYCN MODEL  
LEADS TO AN EYE TO WING HOMEOTIC TRANSFORMATION  
THROUGH DEREGLATION OF HOMEOTIC GENES' EXPRESSION.
- 3:20 p.m. – 3:45 p.m.**      **Michael D. Hogarty, MD**  
*Children's Hospital of Philadelphia, Philadelphia, PA*  
BOTH CANCER CELL INTRINSIC AND IMMUNE  
MICROENVIRONMENT EFFECTS CONTRIBUTE TO THE ANTI-TUMOR  
ACTIVITIES OF POLYAMINE DEPLETING THERAPIES IN  
NEUROBLASTOMA.
- 3:45 p.m. – 4:00 p.m.**      **BREAK**
- 4:00 p.m. – 4:25 p.m.**      **Jed G. Nuchtern, MD**  
*BCM, Pediatrics, Surgery, Houston, TX*  
EWS-FLI1 AND RNA HELICASE A INTERACTION INHIBITOR  
YK-4-279 INHIBITS GROWTH OF NEUROBLASTOMA.
- 4:25 p.m. – 4:50 p.m.**      **Jason Shoheit, MD, PhD**  
*BCM, Pediatrics, Hematology/Oncology, Houston, TX*  
SINGLE CELL RNASEQ ANALYSIS OF NEUROBLASTOMA CANCER  
STEM CELL SUBPOPULATIONS.
- 4:50 p.m. – 5:15 p.m.**      **Eveline Barbieri, MD, PhD**  
*BCM, Pediatrics, Hematology/Oncology, Houston, TX*  
TARGETING MYCN-MEDIATED METABOLIC REPROGRAMMING.
- 5:15 p.m. – 6:00 p.m.**      **Rani E. George, MD, PhD**  
*Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA*  
RESISTANCE TO ALK INHIBITION IN NEUROBLASTOMA.

▲ **SESSION II • 8:00 a.m. - 12:00 p.m.**

**Session: Epigenetics/Translational**

**Chairperson: Jason Shoet, Houston, TX**

- 7:15 a.m. – 8:00 a.m.      **BREAKFAST**
- 8:00 a.m. – 8:15 a.m.      **WELCOME**  
**David Poplack, MD**  
*Elise C. Young Professor of Pediatric Oncology  
Head, Hematology-Oncology Section  
Department of Pediatrics  
Baylor College of Medicine and  
Director, Texas Children's Cancer Center  
Texas Children's Hospital*
- Christopher and Laurie Declaire**  
*Laurie Declaire - Board Member, TCCC; Founder, Trees for Life  
Christopher and Laurie Declaire - parents of "Captain Courageous"*
- 8:15 a.m. – 8:40 a.m.      **Andrew M. Davidoff, MD**  
*St. Jude Children's Research Hospital, Memphis, TN*  
THE ROLES OF HISTONE DEMETHYLASES IN NEUROBLASTOMA.
- 8:40 a.m. – 9:05 a.m.      **Saurabh Agarwal, PhD**  
*BCM, Pediatrics, Hematology/Oncology, Houston, TX*  
EPIGENETIC REGULATION OF NEUROBLASTOMA  
TUMORIGENICITY THROUGH MLL1 AND JMJD3 MODULATION IN  
CANCER STEM CELLS.
- 9:05 a.m. – 9:30 a.m.      **Carol J. Thiele, PhD**  
*National Cancer Institute, Bethesda, MD*  
INTERROGATION OF EPIGENETIC LANDSCAPE OF  
NEUROBLASTOMA IDENTIFIES THERAPEUTICALLY RELEVANT  
VULNERABILITIES.
- 9:30 a.m. – 9:55 a.m.      **Jan J. Molenaar, MD**  
*Prinses Maxima Center for Pediatric Oncology, Utrecht,  
The Netherlands*  
TOWARDS BIOMARKER BASED COMBINATION TRIALS.
- 9:55 a.m. – 10:10 a.m.      **BREAK**
- 10:10 a.m. – 10:35 a.m.      **Pieter Mestdagh, PhD**  
*Cancer Research Institute Ghent (CRIG), Ghent University, Belgium*  
CANCER-SPECIFIC LNCRNAs AS NOVEL BIOMARKERS AND  
TARGETS FOR THERAPY.
- 10:35 a.m. – 11:00 a.m.      **Johannes H. Schulte, MD**  
*Charite Universitäts Medizin Berlin, Germany*  
BET-BROMODOMAIN INHIBITION AS A THERAPEUTIC  
STRATEGY TO TREAT MYCN-AMPLIFIED NEUROBLASTOMA.
- 11:00 a.m. – 12:00 p.m.      **Jason Heaney, PhD**  
*BCM, Pediatrics, Hematology/Oncology, Houston, TX*  
CRISPR/CAS9 EDITING OF THE MOUSE GENOME:  
CURRENT APPROACHES AND DEVELOPING TECHNOLOGIES.
- 12:00 p.m. – 1:15 p.m.      **LUNCH / FREE TIME**

 **SESSION III • 1:15 p.m. - 6:00 p.m.**

**Session: Clinical/Translational**

**Chairperson: Jennifer Foster, Houston, TX**

- 1:15 p.m. – 1:25 p.m.      **Patricia Tallungan - President and Founder**  
*Children's Neuroblastoma Cancer Foundation (CNCF)*
- 1:25 p.m. – 1:35 p.m.      **Vicki Buenger - President and Founder**  
*Coalitional Against Childhood Cancer (CAC2)*
- 1:35 p.m. – 2:00 p.m.      **Rochelle Bagatell, MD**  
*Children's Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, PA*  
RANDOMIZED PHASE II TRIAL OF IRINOTECAN/TEMOZOLOMIDE (I/T) WITH TEMSIROLIMUS (TEM) OR DINUTUXIMAB PLUS GRANULOCYTE COLONY STIMULATING FACTOR (DIN/GMCSF).
- 2:00 p.m. – 2:25 p.m.      **Susan Cohn, MD**  
*University of Chicago Medicine, Chicago, IL*  
UPDATING THE COG NEUROBLASTOMA RISK STRATIFICATION USING THE INRG STAGING SYSTEM.
- 2:25 p.m. – 2:50 p.m.      **Steven DuBois, MD, MS**  
*Dana Farber, Boston Children's Cancer and Bleeding Disorders Center. Boston, MA*  
STRATEGIES TO OPTIMIZE 131I-MIBG THERAPY FOR PATIENTS WITH ADVANCED NEUROBLASTOMA.
- 2:50 p.m. – 3:05 p.m.      **BREAK**
- 3:05 p.m. – 3:30 p.m.      **Mark A. Applebaum, MD**  
*University of Chicago Medicine, Chicago, IL*  
NEUROBLASTOMA SURVIVORS ARE AT INCREASED RISK FOR SECOND MALIGNANCIES: A REPORT FROM THE INTERNATIONAL NEUROBLASTOMA RISK GROUP PROJECT.
- 3:30 p.m. – 3:55 p.m.      **Meaghan Granger, MD**  
*Cook Children's Health Care System, Dallas, TX*
- 3:55 p.m. – 4:20 p.m.      **Kevin Freeman, PhD**  
*St. Jude Children's Research Hospital, Memphis, TN*  
ARID1A HAPLOINSUFFICIENCY IN NEURAL CREST DERIVED TUMORS.
- 4:20 p.m. – 4:45p.m.      **Katleen De Preter, PhD**  
*Center for Medical Genetics Ghent (CMGG), Cancer Research Institute Ghent (CRIG), Ghent University, Belgium*  
NEUROBLASTOMA CELL IDENTITY GENES ALTERED BY DNA COPY NUMBER CHANGES.

 **POSTER SESSION • 4:45 p.m. - 6:00 p.m.**

4:45 p.m. – 6:00 p.m.      **POSTER SESSION**



**SESSION IV • 8:00 a.m. - 12:00 p.m.**

**Session: Clinical/Translational**

**Chairperson: Leonid S. Metelitsa, Houston, TX**

- 7:15 a.m. – 8:00 a.m.                      BREAKFAST**
- 8:00 a.m. – 8:25 a.m.                      Jennifer Foster, MD, MPH**  
*BCM, Pediatrics, Hematology/Oncology, Houston, TX*  
TARGETING NEDD8: A NOVEL APPROACH TO TREATING NEUROBLASTOMA.
- 8:25 a.m. – 8:50 a.m.                      Julie Park, MD**  
*Seattle Children's Hospital, Seattle, WA*  
ENGINEERED NEUROBLASTOMA CELLULAR IMMUNOTHERAPY (ENCIT)-01: A PHASE 1 STUDY OF AUTOLOGOUS T-CELLS LENTIVIRALLY TRANSDUCED TO EXPRESS CD171-SPECIFIC CHIMERIC ANTIGEN RECEPTORS (CAR) FOR RECURRENT/ REFRACTORY HIGH-RISK NEUROBLASTOMA (HR-NB).
- 8:50 a.m. – 9:15 a.m.                      Samuel Volchenbom, MD, PhD**  
*University of Chicago Medicine, Chicago, IL*  
THE INTERNATIONAL NEUROBLASTOMA RISK GROUP DATA COMMONS.
- 9:15 a.m. – 9:40 a.m.                      Jun S. Wei, PhD**  
*National Cancer Institute, Bethesda, MD*  
RNA-SEQ ANALYSIS IDENTIFIED IMMUNE SIGNATURES ASSOCIATED WITH THE OUTCOME IN PATIENTS WITH HIGH-RISK NEUROBLASTOMA.
- 9:40 a.m. – 10:05 a.m.                      Dai Chung, MD**  
*Vanderbilt Children's Hospital, Nashville, TN*  
ML327 BLOCKS N-MYC EXPRESSION AND TUMOR FORMATION IN MYCN-AMPLIFIED NEUROBLASTOMAS.
- 10:05 a.m. – 10:20 a.m.                      BREAK**
- 10:20 a.m. – 10:45 a.m.                      Shahab Asgharzadeh, MD**  
*The Saban Research Institute of Children's Hospital Los Angeles, University of Southern California*  
TARGETING TUMOR-ASSOCIATED MACROPHAGES TO ENHANCE EFFECTIVENESS OF IMMUNE CHECKPOINT AND OTHER IMMUNOTHERAPIES.
- 10:45 a.m. – 11:10 a.m.                      Leonid S. Metelitsa, MD, PhD**  
*BCM, Pediatrics, Hematology/Oncology, Houston, TX*  
IMMUNOTHERAPY OF NEUROBLASTOMA WITH CAR NKT CELLS.
- 11:10 a.m. – 11:25 a.m.                      Robin Parihar, MD, PhD**  
*BCM, Pediatrics, Hematology/Oncology, Houston, TX*  
THE NEUROBLASTOMA TUMOR MICROENVIRONMENT IMPAIRS THE ACTIVITY OF CAR-T CELLS AND CAN BE TARGETED BY CHIMERIC ACTIVATING RECEPTOR-BEARING NATURAL KILLER CELLS.

